Despite the therapeutic resistance of FLT3-mutated AML, AML blasts harboring FLT3-ITD and TKD mutations are sensitive to small molecule inhibitors; as such, these targeted FLT3 inhibitors are an important part of the therapeutic approach to treating patients with FLT3-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.